Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.

Chongqing, Tan; Sini, Li; Xiaohui, Zeng; Liubao, Peng; Ye, Peng; Shuxia, Qin; Liting, Wang; Meiyu, Wu; Xiaomin, Wan

Chongqing, Tan; Sini, Li; Xiaohui, Zeng; Liubao, Peng; Ye, Peng; Shuxia, Qin; Liting, Wang; Meiyu, Wu; Xiaomin, Wan.

Afiliación

Chongqing T; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Sini L; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Xiaohui Z; School of Health and Related Research, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
Liubao P; PET Imaging Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Ye P; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Shuxia Q; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Liting W; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Meiyu W; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Xiaomin W; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.

Front Pharmacol ; 12: 802942, 2021.

Article en En | MEDLINE | ID: mdl-34970153

Palabras clave

colorectal neoplasms; cost-effectiveness; immunotherapy; microsatellite-instability-high/mismatch repair-deficient; pembrolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google